Mentor Plots Cosmetic Change
The prospective reshaping of the cosmetic-medicine sector had already created plenty of drama in recent days, but now there's a new wrinkle in what has become a four-player saga.
On Sunday, Mentor (MNT) made things a little more interesting, offering $2.2 billion for Medicis Pharmaceutical (MRX). Upon learning of the proposal, Medicis' board members immediately rejected it and reaffirmed their own desire to continue pursuing Inamed (IMDC).
Allergan and Medicis want Inamed's existing and experimental skin-treatment products. Medicis hopes to expand its skin-care and skin-disease offerings, while Allergan is aiming to fortify its Botox business and to repel challenges from Medicis. Allergan's exchange offer for Inamed began Monday.Mentor likes Medicis for its skin-treatment business, which it believes has better prospects than its own urological products. Mentor has hired an investment bank to explore options for its urology businesses. The fight could become even more complicated. After Allergan made its bid for Inamed, analysts began speculating that someone would try to buy Mentor, of Santa Barbara, Calif. That speculation hasn't diminished.
Into the FrayBy early afternoon, shares of Mentor were down $4.89, or 8.7%, to $51.25 as some analysts said its bid was the weakest of all the proposals. More than 1.7 million shares traded, or triple the daily average for the past three months. Medicis jumped $4.34, or 15.6%, to $32.09, on nearly four times the average daily volume for the past three months. Mentor offered 0.62 shares for each Medicis share, implying a value of $34.69 a share. That's 25% higher than the Scottsdale, Ariz., company's closing price on Friday. Joshua H. Levine, Mentor's chief executive, said that even though his stock-swap offer would give Medicis shareholders a 44% stake in the combined company, he would be willing to add cash to the formula to make the proposal more palatable. He didn't offer a precise figure, saying only that the cash component could be "significant or substantial."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV